1. Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment 
Juul M.P.A. van den Reek, MD, Philippe A.R.R. Pijls, MD, Marcia Tummers, PhD, Piet C.L.M. van Riel, MD, PhD, Wietske Kievit, PhD, Frank Hoentjen, MD, PhD, Elke M.G.J. de Jong, MD, PhD 
Journal of the American Academy of Dermatology 
Volume 74, Issue 1, Pages (January 2016)
DOI: /j.jaad
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Overall adalimumab drug survival in patients with plaque psoriasis (PP) (n = 115), Crohn's disease (CD) (n = 168), and rheumatoid arthritis (RA) (n = 176).
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Hazard ratios corrected for variables that explained differences in adalimumab drug survival between plaque psoriasis (PP), Crohn's disease (CD) and rheumatoid arthritis (RA) (n = 459).
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions